Infectious disease Archives

avian influenza flu bird pandemic nature host imperial

News and Trends 14 Jan 2016

Angry birds: How does Avian Influenza Virus infect Human cells?

What does the bird flu virus have to change in order to takeover the human cell machinery? For the first time, researchers from Imperial College London have identified the pathway that allows Avian flu virus to hop from bird’s to mammalian cells. Influenza pandemics aren’t easy to predict: outbreaks occur when zoonotic influenza viruses suddenly […]

January 14, 2016 - 3 minutesmins - By Lourdes Riquelme

HIV abivax Alexey Kashpersky abx464 trial antiviral

News and Trends 13 Jan 2016

A Phase II HIV Antiviral from France Has Promising Results

Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market. HIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the […]

January 13, 2016 - 3 minutesmins - By Dani Bancroft

clostridium difficile microbiomics seres health therapeutics nestle science crohns ibd uc cdi

News and Trends 12 Jan 2016

Microbiomics and Nestlé: €1.7Bn for New TransAtlantic Drug Development Program

Microbiomics is a hot area for biotech. Now US Seres Therapeutics and Nestlé Health Sciences have signed a massive drug development deal for bowel diseases and C.difficile infections. By correcting the fundamental microbiome dysbiosis that is the root cause of many diseases, Seres Theraputics in Cambridge (US) is creating a profoundly new and important way […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

In Depth 5 Jan 2016

Ultimate Review: How Could mRNA Overtake all other Biologicals in Medicine?

What if we could send the body an instruction to produce its own drug? That’s what messenger RNA (mRNA) could achieve. A whole new area of therapeutics could be opened. Let’s try to get an overview of how… So for those who don’t know what a mRNA is, here are some basics. This diagram below […]

January 5, 2016 - 7 minutesmins - By Jerome Topsent

ablynx antibodies rsv infection nanobody llama

News and Trends 18 Dec 2015

64 Million RSV Infections Per Year: Perhaps Alpaca Nanobodies Will Save Infant Lives

Ablynx, the Alpaca Nanobody Biotech from Belgium, has completed target enrollment of the first-in-infant Phase I/IIa study with its anti-Respiratory Syncytial virus, which is linked to 3,000-8,500 infant deaths each year. ALX-0171 is a wholly-owned Nanobody drug candidate administered through inhalation (nebulisation), for the treatment of respiratory syncytial virus (RSV) infection in infants. The candidate […]

December 18, 2015 - 3 minutesmins - By Dani Bancroft

ngs bioinformatics biomerieux illumina microbiology immunoassay

News and Trends 16 Dec 2015

Global NGS Leader’s Influence in European Bioinformatics Field is Spreading Interest in Microbiomics

BioMérieux (France) is a diagnostics tech company which has partnered with the US Bioinformatics Giant Illumina to produce a novel Microbiological genetics sequencing kit: the bioMérieux EpiSeq. BioMérieux is a worldwide leading provider of diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and reduce risk of hospital […]

December 16, 2015 - 3 minutesmins - By Dani Bancroft

immbio pneumonia vaccine infection heat shock proteins

News and Trends 10 Dec 2015

A New Vaccine Against Pneumonia and Meningitis Reaches Human Trials..

Pneumonia, Meningitis and Sepsis: All these potentially fatal infections could one day be vaccinated against with Cambridge’s ImmBio and their Pneumococcal vaccine, which has now started safety & tolerability trials in the UK. ImmBio is based at the Babraham Institute, a unit of the UK’s Biotechnology & Biological Sciences Research Council (and in our Listed […]

December 10, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 20 Nov 2015

Biotech of the week: Opsona Therapeutics, The Leading Irish Immuno-Oncology Biotech

This week we say farewell to Austria and head North-West, across the United Kingdom and land in the Emerald Isle, Ireland, where we arrive at our destination, Dublin. The capital city of Ireland is the home of the very famous Irish dry stout, Trinity College (plus its stunning library) and a nearly 900-year-old cathedral. It is […]

November 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 16 Nov 2015

What are Money-Magnet Moderna’s future plans? French Founding CEO explains here

Before the end of the mRNA conference in Berlin, I had to interview Stephane Bancel, the French founding CEO of Moderna…one of the biggest deals in Biotech today. Moderna is the mRNA therapies companies from Cambridge/Boston (US), most famous for having raised over 900 million dollars in VC money. I met Stephane one and a […]

November 16, 2015 - 1 minutemin - By Philip Hemme

News and Trends 13 Nov 2015

Curetis Molecular Diagnostics IPO Exceeds Expectations

The Southern German Med-tech for infectious disease biotech, Curetis, has sold shares up to a value of €40M, which is 10 million above its initial target, despite a lower ranged Offer price. Curetis have developed a molecular diagnostics system for hospital acquired infections (such as MRSA and Pneumonia). Their Unyvero system is a piece of […]

November 13, 2015 - 2 minutesmins - By Dani Bancroft

seasonal influenza universal vaccine sanofi peptcell seek niaid nihr

News and Trends 12 Nov 2015

Sanofi’s COBRA Research to Tackle the Challenge of A Universal Influenza Vaccine for Winter

Sanofi Pasteur is the infectious disease division of the French Giant Sanofi, responsible for producing 1 Billion vaccine doses each year. Now they are looking to ‘evolve’ the vaccine R&D field, adapting their approach to find a broader spectrum defense against seasonal Influenza strains. However, the UK NIHR and PepTCell are also after the same […]

November 12, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 12 Nov 2015

Interview: CureVac, the ‘RNA’ People’s Pioneering Strategy to get mRNA Therapies onto the Market

I am still at the mRNA Convention in Berlin…and was invited for a second interview – this time with the ‘RNA People’, battling to be the first to get an mRNA Drug onto the Worldwide Market. I had a chat with Franz-Werner Haas, the Chief Corporate Office of CureVac. We talked a lot about this […]

November 12, 2015 - 1 minutemin - By Philip Hemme

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us